Ali Haluk DÜZKALIR

Dr. Ali Haluk DÜZKALIR

Neurosurgery, Koç University, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
SÖSelçuk Özdoğan
Selçuk Özdoğan
CSCeyhun Saymaz
Ceyhun Saymaz
CYCumhur Kaan Yaltırık
Cumhur Kaan Yaltırık
HDHanife Gülden Düzkalır
Hanife Gülden Düzkalır
MKMustafa Kaya
Mustafa Kaya
BABerrin Aktekin
Berrin Aktekin
BACKGROUND:Encephalocraniocutaneous lipomatosis (ECCL) was first announced as a new type of ectomesodermal dysgenesis in 1970 by Haberland and Perou. ECCL was first described in 1970, and approximately 60 cases have been reported since then. The clas...

2 June 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
SOSelcuk Ozdogan
Selcuk Ozdogan
CYCumhur Kaan Yaltirik
Cumhur Kaan Yaltirik
SYSeda Gulec Yilmaz
Seda Gulec Yilmaz
FAFatma Tuba Akdeniz
Fatma Tuba Akdeniz
KSKadir Sumerkent
Kadir Sumerkent
TITurgay Isbir
Turgay Isbir
Background/Aim: The aim of our study was to examine miRNA-221 as a candidate biomarker to define prognosis and/or classification for glial tumors. Materials and Methods: This study included 39 patients who underwent glial tumor surgery and 40 healthy individuals as the control group. miRNA expression levels were determined by real-time polymerase chain reaction (RT-PCR). Receiver operating characteristic curve analysis was used for analyzing the predictive ability of miRNA-221. Results: The levels of miRNA-221 expression were determined by comparing the ΔCT values of miRNAs and the internal control. When the expression levels of miRNA-221 were compared according to the ΔCT method, miRNA-221 was found to be significantly increased in the patient group compared to the control group (p<0.0001). Conclusion: Increased expression levels of miRNA-221 could be a biomarker for glial tumors.

22 February 2024 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
YSYavuz Samanci
Yavuz Samanci
EMElif Mürdün
Elif Mürdün
MÇMahmut Çil
Mahmut Çil
ADAli Haluk DÜZKALIR
Ali Haluk DÜZKALIR
MAMehmet Orbay Askeroglu
Mehmet Orbay Askeroglu
SPSelcuk Peker
Selcuk Peker

21 February 2024 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
YSYavuz Samanci
Yavuz Samanci
MTMehmet Ali Tepebasili
Mehmet Ali Tepebasili
GAGokce Deniz Ardor
Gokce Deniz Ardor
ADAli Haluk DÜZKALIR
Ali Haluk DÜZKALIR
MAM. Orbay Askeroglu
M. Orbay Askeroglu
Selçuk PekerSelçuk Peker
Selçuk Peker

13 November 2023 in Neurosurgery
Verified
Journal Article
Closed access
NDNülifer Kilic Durankus
Nülifer Kilic Durankus
YSYavuz Samanci
Yavuz Samanci
ADAli Haluk DÜZKALIR
Ali Haluk DÜZKALIR
Selçuk PekerSelçuk Peker
Selçuk Peker
BACKGROUND AND OBJECTIVES: Tectal plate gliomas (TPGs) are midbrain tumors that grow slowly and have a benign clinical course. Most TPGs are low-grade astrocytomas, but they can encompass various histological tumor types. Gamma Knife radiosurgery (GKRS) is being explored as a potentially safe and effective treatment option for TPGs, although research in this area is limited. This study aims to evaluate GKRS's efficacy and safety in patients with TPG and provide a comprehensive review of existing literature on the topic. METHODS: This retrospective, single-center study included 48 patients with consecutive TPG who underwent GKRS between September 2005 and June 2022. Patients diagnosed with TPGs based on radiological or tissue-based criteria and who had a minimum follow-up period of 12 months were eligible for inclusion. The primary end points were local control and the absence of GKRS-associated or tumor-associated mortality and morbidity. RESULTS: During a median follow-up of 28.5 months (range, 12-128), the radiological assessment showed tumor control in all cases, with 16.7% achieving a complete response and 68.8% achieving a partial response. Pseudoprogression occurred in 6.2% of cases, with onset ranging from 3 to 8 months. Clinical outcomes revealed no permanent neurological deterioration, with symptoms improving in 14.6% of patients and remaining stable in the others. One patient in the pseudoprogression group experienced transient Parinaud syndrome. One patient died during follow-up because of unrelated causes. The mean survival time after GKRS was 123.7 months. None of the clinical, radiological, or radiosurgical variables showed a correlation with partial/complete response, clinical improvement, or overall survival. CONCLUSION: There is limited research available on the management of TPGs, and this study presents the largest patient cohort treated with GKRS, along with a substantial follow-up duration. Despite its limitations, this study demonstrates the efficacy and low-risk profile of GKRS for TPGs.

28 November 2017 in American Journal of Case Reports
Verified
Journal Article
Open access
PDF file
SÖSelçuk Özdoğan
Selçuk Özdoğan
MKMustafa Kaya
Mustafa Kaya
NDNail Demirel
Nail Demirel
ADAli Haluk DÜZKALIR
Ali Haluk DÜZKALIR
CYCumhur Kaan Yaltırık
Cumhur Kaan Yaltırık
BACKGROUND:Total spondylolisthesis, or dislocation of 1 cervical vertebrae, is only caused by high-energy trauma and is usually fatal. Cervical spine fractures and dislocations often cause 3-column structural damage to the cervical spine, injury to t...